| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proteomics and Protein Markers |
1 Department of Medical Chemistry and Biochemistry, Division of Clinical Biochemistry, and2 Clinical Department of Internal Medicine, Clinical Division of Cardiology, Innsbruck Medical University, Innsbruck, Austria.
aAddress correspondence to this author at: Department of Medical Chemistry and Biochemistry, Division of Clinical Biochemistry, Innsbruck Medical University, Fritz-Pregl-Strasse 3, A-6020 Innsbruck, Austria. Fax 43-512-507-2876; e-mail Angelika.Lercher{at}uibk.ac.at.
Background: We compared the performance of different natriuretic peptides to diagnose mild forms of left ventricular dysfunction (LVD) and investigated the influence of measuring B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) with different assays on the diagnostic performance of these markers.
Methods: We measured BNP (Triage® BNP), NT-proBNP (Biomedica), and N-terminal pro-A-type natriuretic peptide (NT-proANP; Biomedica) in 130 consecutive patients (age range, 28–83 years) with clinically suspected mild LVD. In patients with sufficient sample volume, we measured BNP and NT-proBNP with additional assays (Shionoria and Roche, respectively).
Results: For identifying patients with mild systolic LVD, BNP and NT-proBNP were the best markers, with mean (95% confidence interval) areas under the curves (AUC) of 0.78 (0.63–0.89) and 0.75 (0.58–0.87), respectively. However, the diagnostic performance of NT-proANP [AUC, 0.64 (0.48–0.77)] was significantly worse than that of BNP (P = 0.014). Both BNP assays (Triage and Shionoria) and both NT-proBNP assays (Biomedica and Roche) performed equally well for the diagnosis of systolic LVD despite the poor agreement between NT-proBNP assays. In patients with isolated diastolic LVD, the diagnostic performance of the Triage BNP [AUC, 0.70 (0.56–0.81)] was significantly better (P = 0.006) than that of Biomedica NT-proBNP [0.49 (0.34–0.65)]. Furthermore, the performance of the Biomedica NT-proBNP assay was significantly worse (P = 0.03) than that of the Roche NT-proBNP assay for diagnosis of isolated diastolic LVD.
Conclusions: The performance of BNP for the diagnosis of systolic or diastolic LVD is not affected by the assay used, whereas the performance of NT-proBNP for the diagnosis of isolated diastolic LVD is assay dependent.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  R. W. Troughton and A. M. Richards B-type natriuretic peptides and echocardiographic measures of cardiac structure and function. J. Am. Coll. Cardiol. Img., February 1, 2009; 2(2): 216 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Emdin, C. Passino, C. Prontera, M. Fontana, R. Poletti, A. Gabutti, C. Mammini, A. Giannoni, L. Zyw, G. Zucchelli, et al. Comparison of Brain Natriuretic Peptide (BNP) and Amino-Terminal ProBNP for Early Diagnosis of Heart Failure Clin. Chem., July 1, 2007; 53(7): 1289 - 1297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Galasko, P. O Collinson, S. C Barnes, D. Gaze, A. Lahiri, and R. Senior Comparison of the clinical utility of atrial and B type natriuretic peptide measurement for the diagnosis of systolic dysfunction in a low-risk population J. Clin. Pathol., May 1, 2007; 60(5): 570 - 572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Clerico, M. Fontana, L. Zyw, C. Passino, and M. Emdin Comparison of the Diagnostic Accuracy of Brain Natriuretic Peptide (BNP) and the N-Terminal Part of the Propeptide of BNP Immunoassays in Chronic and Acute Heart Failure: A Systematic Review Clin. Chem., May 1, 2007; 53(5): 813 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Herrmann, O. Taban-Shoma, U. Hubner, A. Pexa, H. Kilter, N. Umanskaya, R. Hans Straub, M. Bohm, and W. Herrmann Hyperhomocysteinemia and Myocardial Expression of Brain Natriuretic Peptide in Rats Clin. Chem., April 1, 2007; 53(4): 773 - 780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Persson, E. Lonn, M. Edner, L. Baruch, C. C. Lang, J. J. Morton, J. Ostergren, R. S. McKelvie, and for the Investigators of the CHARM Echocardiograph Diastolic Dysfunction in Heart Failure With Preserved Systolic Function: Need for Objective Evidence: Results From the CHARM Echocardiographic Substudy-CHARMES J. Am. Coll. Cardiol., February 13, 2007; 49(6): 687 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Herrmann, S. Muller, I. Kindermann, L. Gunther, J. Konig, M. Bohm, and W. Herrmann Plasma B vitamins and their relation to the severity of chronic heart failure Am. J. Clinical Nutrition, January 1, 2007; 85(1): 117 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Aspromonte, V. Ceci, A. Chiera, C. Coletta, A. D'Eri, M. Feola, P. Giovinazzo, L. Milani, F. Noventa, A. B. Scardovi, et al. Rapid Brain Natriuretic Peptide Test and Doppler Echocardiography for Early Diagnosis of Mild Heart Failure Clin. Chem., September 1, 2006; 52(9): 1802 - 1808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hammerer-Lercher, R. Geiger, J. Mair, C. Url, G. Tulzer, E. Lechner, B. Puschendorf, and R. Sommer Utility of N-Terminal Pro-B-Type Natriuretic Peptide to Differentiate Cardiac Diseases from Noncardiac Diseases in Young Pediatric Patients Clin. Chem., July 1, 2006; 52(7): 1415 - 1419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Costello-Boerrigter, G. Boerrigter, M. M. Redfield, R. J. Rodeheffer, L. H. Urban, D. W. Mahoney, S. J. Jacobsen, D. M. Heublein, and J. C. Burnett Jr Amino-Terminal Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide in the General Community: Determinants and Detection of Left Ventricular Dysfunction J. Am. Coll. Cardiol., January 17, 2006; 47(2): 345 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Tschope, M. Kasner, D. Westermann, R. Gaub, W. C. Poller, and H.-P. Schultheiss The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements Eur. Heart J., November 1, 2005; 26(21): 2277 - 2284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. I.W. Galasko, A. Lahiri, S. C. Barnes, P. Collinson, and R. Senior What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? Eur. Heart J., November 1, 2005; 26(21): 2269 - 2276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Crimmins Human N-Terminal proBNP Is a Monomer Clin. Chem., June 1, 2005; 51(6): 1035 - 1038. [Full Text] [PDF]
|
|
|
|
|
|
A. Clerico, C. Prontera, M. Emdin, C. Passino, S. Storti, R. Poletti, L. Zyw, and G. C. Zucchelli Analytical Performance and Diagnostic Accuracy of Immunometric Assays for the Measurement of Plasma B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP Clin. Chem., February 1, 2005; 51(2): 445 - 447. [Full Text] [PDF]
|
|
|
|
|
|
K.-M. Hermann-Arnhof, U. Hanusch-Enserer, T. Kaestenbauer, T. Publig, A. Dunky, H. R. Rosen, R. Prager, and U. Koller N-Terminal Pro-B-Type Natriuretic Peptide as an Indicator of Possible Cardiovascular Disease in Severely Obese Individuals: Comparison with Patients in Different Stages of Heart Failure Clin. Chem., January 1, 2005; 51(1): 138 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rej Clinical Chemistry through Clinical Chemistry: A Journal Timeline Clin. Chem., December 1, 2004; 50(12): 2415 - 2458. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
